Advanced search
Start date
Betweenand

Methylation pattern of Genomic DNA in mesial temporal lobe epilepsy associated with hippocampal sclerosis

Grant number: 17/23954-0
Support type:Scholarships in Brazil - Master
Effective date (Start): April 01, 2018
Effective date (End): February 29, 2020
Field of knowledge:Health Sciences - Medicine
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal Investigator:Iscia Teresinha Lopes Cendes
Grantee:Jaqueline Cruz Geraldis
Home Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
Associated research grant:13/07559-3 - BRAINN - The Brazilian Institute of Neuroscience and Neurotechnology, AP.CEPID

Abstract

Epilepsy is a neurological disease with a high prevalence in the population. It is characterized by paroxysmal episodes of abnormal neuronal activity, resulting in epileptic seizures. Mesial temporal lobe epilepsy (MTLE), which may be associated with hippocampal sclerosis, is one of the most frequent and most severe types of epilepsy, since many patients present medically refractory seizures. In these patients surgical treatment may be a therapeutic alternative, which includes the surgical resection of abnormal cerebral tissue presenting epileptic activity. Such tissue allows for experiments to investigate gene expression regulation. Thus, the main objective of our work is to determine the overall methylation pattern of genomic DNA, the metilome, in tissue from patients with MTLE and compared it to normal brain tissue obtained from autopsy. In addition, we will correlate the metiolome data with the transcriptome and proteome profiles obtained from these patients in order to determine a more complete picture of mechanisms determining gene expression regulation in MTLE. We believe that our results will identify key molecular pathways that can be modulated or modified in future experiments, contributing to current efforts aimed at improving therapeutic interventions for patients with severe forms of epilepsy. (AU)